Our News

Servier signed a definitive agreement to acquire Symphogen

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

06/04/2020

Rgenta Therapeutics recipient of the Servier’s 2020 LabCentral Golden Ticket

05/05/2020

Health Innovation Coalition Innovation in response to the Covid-19 health crisis

20/03/2020

Cellectis and Servier Expand Collaboration on UCART19 Products

19/02/2020

Servier signed a definitive agreement to acquire Symphogen